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This is a report of the first Plasmodium vivax congenital malaria case in Guatemala and the first case in Latin
America with genotypical, histological and clinical characterization. The findings show that maternal P. vivax
infection still occurs in areas that are in the pathway towards malaria elimination, and can be associated with
detrimental health effects for the neonate. It also highlights the need in very low transmission areas of not only
maintaining, but increasing awareness of the problem and developing surveillance strategies, based on population
risk, to detect the infection especially in this vulnerable group of the population.
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Congenital malaria (CM) has been an often neglected con-
sequence of malaria in pregnancy. It occurs when malaria
parasites cross the placenta either during pregnancy or at
delivery [1-3]. There is not much consensus regarding its
definition. It has been defined as the presence of asexual
parasites in the neonate’s peripheral blood within the first
seven days of life or later if there is no exposure to
infected mosquito bites, with or without clinical symp-
toms or signs [4]. Also, CM is often reported as the pres-
ence of malaria parasites in cord blood [3].
Congenital malaria has been predominantly reported
for Plasmodium falciparum and from sub-Saharan Africa
[5-7]. The precise prevalence of CM remains unclear, as it
varies widely across endemic areas, ranging from 0.2% to
46.7% [5,6,8]. The use of PCR methods have revealed a
higher frequency than it was previously reported [9-12].
Little information exists on its consequences for infant’s
health, although it has been described that CM may lead* Correspondence: abardaji@clinic.ub.es
†Equal contributors
2Barcelona Centre for International Health Research, (CRESIB, Hospital Clínic-
Universitat de Barcelona), Roselló, 132, 5-1, 08036, Barcelona, Spain
Full list of author information is available at the end of the article
© 2012 Castellanos et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumto increased morbidity and mortality of the newborn if
not accurately diagnosed and treated [13,14]. Moreover,
prompt and effective malaria treatment during pregnancy
has proven to be a protective factor for CM [14].
In Latin America, reports on CM have been scarce
[9,15,16]; also, the effects of Plasmodium vivax congeni-
tal mono-infection on the neonate’s health have not yet
been reported. This is the first P. vivax CM case from
Guatemala and the first case in Latin American in which
a comprehensive clinical, histological and genotypical in-
vestigation has been carried out.
Case report
On September 2010, a 21-days-old female baby with a
two-day history of fever was admitted to Fray Bartolomé
de las Casas (FBC) District Hospital. FBC is a rural low-
transmission malaria endemic area (population 55,073 inha-
bitants) in Northern Guatemala. FBC was a high-risk area
where malaria transmission has been greatly reduced over
the last years due to a scale-up of control interventions.
Long-lasting insecticide-treated nets (LLITNs) and the im-
provement of the case management system implemented
from 2006, resulted in a dramatic reduction in malaria
parasite incidence from 91/1,000 population in 2006 to 1.9/tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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arum has been reported in the FBC area (National Malaria
Control Program, Guatemala; unpublished data). Malaria
transmission is sustained in the population by the temporal
succession of the main vectors, Anopheles albimanus,
Anopheles vestitipennis and Anopheles darlingi [17].
On admission physical examination of the baby revealed
paleness, hepatosplenomegaly (1 cm), dusky skin appear-
ance and desquamation, and a body temperature of 36.7°C
which increased to 38.9°C in the next 24 hours. Neuro-
logical, respiratory and cardiac examinations were unre-
markable. Main laboratory findings were anaemia (Hb
7.2 g/dL), severe thrombocytopaenia (45,000 platelets/μL
on the 1st day of admission, 24,000 platelets/μL on the
2nd day of admission), and leucopaenia (white blood
cells 3.5x103/μL) with relative lymphocytosis (66.8%). Yet,
the newborn did not show any signs or symptoms of
haemodynamic failure nor evidence of bleeding through-
out admission or after discharge. Biochemical and micro-
biological examinations were not available in the hospital.
Based on initial suspicion of neonatal sepsis, the baby was
started on intravenous (IV) ampicillin along with IV fluids
and antipyretics. The thick blood smear examination
showed P. vivax infection (parasite density 2,079 asexual
parasites/μL), and then she was started on anti-malarial
treatment with oral chloroquine (CQ) (¼ tablet of CQ
150 mg base, daily for five days). The neonate was treated
with CQ only, following national guidelines in Guatemala
that do not recommend the administration of primaquine
to infants less than six months. Clinical progress was ad-
equate and the baby was discharged after treatment com-
pletion. National guidelines also recommend therapy with
¼ tablet of CQ 150 mg base every 21 days until the patient
is six months of age, so the infant kept on with CQ
prophylaxis until that age after treatment completion.
Follow-up during household visits two and eight months
after hospital discharge was also favourable.
The 23-year-old primigravid mother was a FBC per-
manent resident. She was enrolled at the first antenatal
clinic (ANC) visit, at 16 weeks of gestational age, in a
multi-centre descriptive study –PregVax study- aimed to
determine the burden and impact of P. vivax infection
in pregnancy. As part of the PregVax study, maternal
peripheral blood was collected at each ANC visit and at
delivery for active detection of Plasmodium infection by
microscopy and molecular methods. Samples were also
collected from cord, placental, and newborn’s peripheral
blood by heel prick at delivery for parasitaemia deter-
mination by microscopy and molecular methods, and
placental impression smear and biopsy were taken for
microscopic and histological examination, respectively.
This is a retrospective congenital malaria case report
that mainly builds on the hospital clinical data available
during its management. Molecular analyses, which wereavailable due to the mother’s participation in the main
study and carried out after the detection of CM infec-
tion, allowed the confirmation of the malaria case.
Plasmodium infection was not detected in the mother,
either actively or passively, during pregnancy, neither by
microscopy nor by polymerase chain reaction (PCR) at
any of the ANC at 16, 21 and 26 weeks of gestational age.
Delivery was at term (40 weeks), and the birth weight
was 2,839 g. At delivery, the mother reported fever within
the last 24 hours. Physical examination showed an axillary
temperature of 38°C, paleness, and laboratory tests
showed thrombocytopaenia (46,000 platelets/μL) and
haemoglobin of 12.4 g/dL. Plasmodium vivax asexual
parasites (6,429 parasites/μL) were detected in peripheral
blood (see Table 1). She was treated with oral CQ
(1,500 mg given over three days) and oral primaquine
(15 mg daily for 14 days), following national guidelines. A
follow-up home visit was conducted by the National Mal-
aria Control Programme staff to assess treatment compli-
ance and confirm parasite clearance.
A placental biopsy sample was collected at delivery
from the maternal side of the placenta, kept at 4°C in
neutral buffer formalin, processed for histological exam-
ination, and stained with haematoxylin and eosin as pre-
viously described [18]. No evidence of parasites or
malaria pigment deposition was found in the histological
examination. Placental impression smears were not as-
sessable due to lack of quality of the samples.
Immediately after birth, physical examination of the
newborn revealed no clinical abnormalities. No Plasmo-
dium infection was detected in the blood thick smear
collected at delivery from the newborn. Examination of
the cord blood thick smear showed P. vivax asexual
parasites (50 parasites/μL). Cord blood parasitaemia de-
termination is not routinely done at this health facility.
In this case, cord blood parasitaemia determination was
done later after birth at the study referral laboratory as
part of the study objectives.
DNA extraction (Purelink TM Genomic DNA Kit – Invi-
trogen) was done on one whole blood-spot on filter paper
from each of the following compartments: maternal per-
ipheral blood at delivery, placental and cord blood, and
neonate’s blood at the time of birth and during hospital ad-
mission. Plasmodium vivax infection was detected by con-
ventional PCR for specific P. vivax merozoite surface
protein 1 gene (Pvmsp1) in all samples except in the new-
born’s blood at the time of birth (Figure 1) [19]. Also, con-
firmation of the presence of P. vivax and absence of P.
falciparum infection was carried out on all samples by
Real-Time PCR with a LightCyclerW 480 system (Roche).
Species-specific primers and probes were used as previ-
ously described by Veron et al. [20], selected from se-
quence of the small subunit of 18S rRNA, according to
the following steps: pre-incubation at 95°C for 10 min;
Table 1 Plasmodium vivax parasitaemia and molecular results from the different compartments and time points










6429 50 Not assessable No parasites nor
malaria pigment
Negative 2079
RT-PCR2,3 + + + Not available Negative +
1 Parasitaemia density was estimated using the patients white blood count.
2 RT = Real-time PCR: + presence of P. vivax DNA.
3 Molecular analyses were carried out after the detection of the congenital malaria case in hospital. All samples at delivery (maternal, cord, placental and newborn
blood) and during admission (newborn) were tested for P.falciparum (microscopy and real-time PCR) and were negative.
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for 5 sec for 50 cycles. All reactions were done in duplicate
in a final volume of 20 μL.
Seven P. vivax microsatellites (MS) were amplified from
P. vivax positive samples as described in Karunaweera
et al. [21]. Briefly, PCR amplifications were performed in a
10-μL reaction mixture containing 2 μL of DNA, 1x reac-
tion buffer, 1.75 mM MgC12, 200 μM of each deoxynu-
cleotide triphosphate, 5 picomoles of each primer and
2.5U of FastStar Taq polymerase (Roche). To determine
the amplicon length variation, PCR products were ana-
lyzed by CEQ 8000 Genetic Analysis System (Beckman
Coulter) using CEQ 8000 software for fragment analysis.
Identical allelic profiles were obtained at the seven MS
loci tested (MS1:231 bp, MS2:210 bp, MS3:177 bp,
MS7:139 bp, MS8:243 bp, MS10:222 bp, MS20:187 bp),
confirming that the same genotype was present in all
compartments.
Discussion
This is the first reported case of P. vivax congenital mal-
aria in Guatemala and the first one from Latin AmericaFigure 1 Molecular detection of Plasmodium vivax in blood
samples from mother and newborn by the amplification of
Pvmsp1 gene. PCR products were separated by electrophoresis
through a 2.2% agarose gel stained with ethidium bromide and
flanked by a 100 bp DNA ladder (Fermentas) as size marker. Lane
MM =Molecular marker 100 bp. Lane M =Maternal peripheral blood
at delivery. Lane C = Umbilical cord blood. Lane P = Placental blood.
Lane N0 = Newborn's blood at birth. Lane N21 = Newborn’s blood
at 21 days of life. Lane C+= Positive Control. Lane C- = Negative Control.with clinical, histological and genotypical characterization.
Co-infection with P. falciparum was excluded by molecu-
lar diagnosis, and the same parasite genotype in maternal
blood at delivery, in placental and cord blood and in per-
ipheral blood of the 21-days-old neonate was detected by
microsatellite genotyping.
Several reports have been published from Latin America
on malaria infection during the neonatal period [15,22,23]
most of them due to P. vivax, but only three were reported
as CM cases [9,15,16]. In none of these cases co-infection
with other Plasmodium species was excluded. Most of the
information on CM comes from high malaria transmission
areas and indicates that CM is rarely symptomatic [3]. Al-
though CM may be associated with non-specific symp-
toms shortly after birth, in most cases the infection is
cleared spontaneously without symptoms. On rare occa-
sions, clinical manifestations may appear within 10 to 42
days after birth [3]. In high endemic areas, passive transfer
of maternal anti-malarial antibodies and the presence of
foetal haemoglobin are thought to prevent disease by help-
ing clearing parasitaemia in the newborn [4].
In the case outlined here, the onset of symptoms oc-
curred 21 days after birth. The possibility that the neo-
nate’s infection was acquired in the short period after
birth from an infected mosquito bite is very low given
the low malaria transmission in the FBC area. The
microsatellite genotyping showing identical allelic pro-
files at all MS loci tested does reinforce the vertical
transmission of the P. vivax infection, however, the pos-
sibility of a new infection, although very unlikely, it can-
not be totally ruled out.
The physiopathology of CM is not well known. It has
been hypothesized that, although the placenta functions
as an effective barrier, maternal micro-transfusions into
the foetal circulation, and direct penetration of the para-
site through the placental villi could lead to vertical
transmission of malaria [3]. In this case, vertical trans-
mission is likely to have occurred around delivery, since
the mother had symptoms at that time and parasitaemia
was detected in maternal and cord blood [24]. The
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presence of parasites or pigment, nor inflammation. The
lack of placental features associated to malaria infection
could be explained by the low density of maternal P.
vivax infection and/or by the absence of a placental
binding phenotype of P. vivax parasites [25].
In a malaria pre-elimination context, as is the case
of the FBC area, the level of acquired anti-malarial
immunity in the population may decreased and waned
dramatically leading to increased susceptibility and risk
of more severe forms of malaria when infection occurs.
This may be particularly frequent and serious in vulner-
able groups of the population, such as pregnant women
and neonates. In the current case, the baby presented
with severe thrombocytopaenia and anaemia, both being
potential life-threatening haematological complications.
This report highlights the need of establishing epidemio-
logical and clinical surveillance strategies as malaria
control programmes are reducing transmission to near-
elimination levels, to effectively and promptly detect
infections [26,27]. The latter would have avoided that
malaria infection in this neonate would have developed
into a life-threatening condition. These measures could
include, firstly increasing clinical awareness since con-
genital malaria may not be considered a cause of illness
in the neonate in such areas, and secondly, the identifi-
cation of the most adequate strategy for active surveil-
lance. This strategy would need to be evidence-informed
on the population risk and based on a cost-effectiveness
approach. Research needs to be done assessing the feasi-
bility and cost-effectiveness of strategies, such as screen-
ing for all febrile babies and follow-up of those born to
mothers who had malaria during pregnancy, whom
should not be so many in low endemic areas.Conclusion
Mother-to-child transmission of P. vivax malaria occurs in
very low malaria endemic settings, and it may be detri-
mental for the infant’s health. These findings emphasize
the relevance in very low transmission areas of not only
maintaining, but even increasing clinical and epidemio-
logical awareness of this preventable and treatable disease
in pregnancy and in the neonate. They also highlight the
need for establishing active surveillance strategies in the
areas that are in the pathway towards malaria elimination.Consent
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